Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

Antiphospholipid syndrome epidemiology and demographics

Introduction

Overview

Overview

The incidence of antiphospholipid syndrome (APS) is approximately 5 cases per 100,000 persons per year. The prevalence of APS is approximately 40-50 cases per 100,000 persons worldwide. APS due to systemic lupus erythematosus (SLE) is more commonly seen in the African American and Hispanic population. Middle aged women are more commonly affected by APS than males.

Epidemiology and Demographics

Epidemiology and Demographics

The epidemiology and demographics of antiphospholipid syndrome is as follows:[1][2][3][4]

Incidence

  • The incidence of antiphospholipid syndrome (APS) is approximately 5 cases per 100,000 persons per year.

Prevalence

  • The prevalence of APS is approximately 40-50 cases per 100,000 persons worldwide.

Case-fatality rate/Mortality rate

  • The case-fatality rate/mortality rate of catastrophic APS is approximately 50%.

Age

  • The commonly affected age groups are young to middle aged adolescents.
  • However, APS is also seen in children and elderly age group.

Race

Gender

  • Middle aged women are more commonly affected by APS than males.

Region

  • There is no particular regional predilection.
References

References

  1. ↑ Cervera R (2017). “Antiphospholipid syndrome”. Thromb Res. 151 Suppl 1: S43–S47. doi:10.1016/S0049-3848(17)30066-X. PMID 28262233.
  2. ↑ Gómez-Puerta JA, Cervera R (2014). “Diagnosis and classification of the antiphospholipid syndrome”. J Autoimmun. 48-49: 20–5. doi:10.1016/j.jaut.2014.01.006. PMID 24461539.
  3. ↑ Lockshin MD (2008). “Update on antiphospholipid syndrome”. Bull NYU Hosp Jt Dis. 66 (3): 195–7. PMID 18937631.
  4. ↑ Gómez-Puerta, Jose A.; Cervera, Ricard (2014). “Diagnosis and classification of the antiphospholipid syndrome”. Journal of Autoimmunity. 48-49: 20–25. doi:10.1016/j.jaut.2014.01.006. ISSN 0896-8411.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Feham Tariq, MD [2]